In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems
- PMID: 10049251
- PMCID: PMC89144
- DOI: 10.1128/AAC.43.3.460
In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems
Abstract
A series of novel aminomethyl tetrahydrofuranyl (THF)-1 beta-methylcarbapenems which have excellent broad-spectrum antibacterial activities exhibit modest efficacies against acute lethal infections (3.8 mg/kg of body weight against Escherichia coli and 0.9 mg/kg against Staphylococcus aureus) in mice when they are administered orally. In an effort to improve the efficacies of orally administered drugs through enhanced absorption by making use of a peptide-mediated transport system, several different amino acids were added at the aminomethyl THF side chains of the carbapenem molecules. The resulting peptidic prodrugs with L-amino acids demonstrated improved efficacy after oral administration, while the D forms were less active than the parent molecules. After oral administration increased (3 to 10 times) efficacy was exhibited with the alanine-, valine-, isoleucine-, and phenylalanine-substituted prodrugs against acute lethal infections in mice. Median effective doses (ED50s) of < 1 mg/kg against infections caused by S. aureus, E. coli, Enterobacter cloacae, or penicillin-susceptible Streptococcus pneumoniae were obtained after the administration of single oral doses. Several of the peptidic prodrugs were efficacious against Morganella morganii, Serratia marcescens, penicillin-resistant S. pneumoniae, extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, and E. coli infections, with ED50s of 1 to 14 mg/kg by oral administration compared with ED50s of 14 to > 32 mg/kg for the parent molecules. In general, the parent molecules demonstrated greater efficacy than the prodrugs against these same infections when the drugs were administered by the subcutaneous route. The parent molecule was detectable in the sera of mice after oral administration of the peptidic prodrugs.
Figures


Similar articles
-
In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.Antimicrob Agents Chemother. 1997 Dec;41(12):2652-63. doi: 10.1128/AAC.41.12.2652. Antimicrob Agents Chemother. 1997. PMID: 9420035 Free PMC article.
-
In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.Antimicrob Agents Chemother. 1999 Mar;43(3):454-9. doi: 10.1128/AAC.43.3.454. Antimicrob Agents Chemother. 1999. PMID: 10049250 Free PMC article.
-
In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem.J Antimicrob Chemother. 1998 Oct;42(4):427-37. doi: 10.1093/jac/42.4.427. J Antimicrob Chemother. 1998. PMID: 9818740
-
Newer carbapenems for urinary tract infections.Int J Antimicrob Agents. 2004 Sep;24 Suppl 1:S35-8. doi: 10.1016/j.ijantimicag.2004.03.001. Int J Antimicrob Agents. 2004. PMID: 15364304 Review.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
Cited by
-
In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.Antimicrob Agents Chemother. 2004 Dec;48(12):4589-96. doi: 10.1128/AAC.48.12.4589-4596.2004. Antimicrob Agents Chemother. 2004. PMID: 15561830 Free PMC article.
-
Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.Drugs. 2001;61(5):553-64. doi: 10.2165/00003495-200161050-00001. Drugs. 2001. PMID: 11368281 Review.
-
Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties.Antimicrob Agents Chemother. 1999 Dec;43(12):2904-9. doi: 10.1128/AAC.43.12.2904. Antimicrob Agents Chemother. 1999. PMID: 10582880 Free PMC article.
References
-
- Agouridas C, Bonnefoy A, Chantot J. Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1995. In vivo antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F171; p. 143.
-
- Finney D. Probit analysis. 3rd ed. London, United Kingdom: Cambridge University Press; 1971.
-
- Fish D, Singletary T. Meropenem, a new carbapenem antibiotic. Pharmacotherapy. 1997;17:644–699. - PubMed
-
- Fukuoka T, Ohya S, Utsui Y, Domon H, Takenouchi T, Koga T, Masuda N, Kawada H, Kakuta M, Kubota M, Ishii C, Sakagawa E, Harasaki T, Hirasawa A, Abe T, Yasuda H, Iwata M, Kuwahara S. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother. 1997;41:2652–2663. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources